A citation-based method for searching scientific literature

Vidyavathi Reddy, Asm Iskander, Clara Hwang, George Divine, Mani Menon, Evelyn R Barrack, G Prem-Veer Reddy, Sahn-Ho Kim. PLoS One 2019
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Biomarker-Guided Development of DNA Repair Inhibitors.
James M Cleary, Andrew J Aguirre, Geoffrey I Shapiro, Alan D D'Andrea. Mol Cell 2020
25
100

Improving outcomes in high-risk prostate cancer with radiotherapy.
William R Polkinghorn, Michael J Zelefsky. Rep Pract Oncol Radiother 2013
10
100

Endogenous DNA Damage as a Source of Genomic Instability in Cancer.
Anthony Tubbs, André Nussenzweig. Cell 2017
443
100

CDK12: an emerging therapeutic target for cancer.
Goldie Y L Lui, Carla Grandori, Christopher J Kemp. J Clin Pathol 2018
29
100

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
Kurt G Pike, Bernard Barlaam, Elaine Cadogan, Andrew Campbell, Yingxue Chen, Nicola Colclough, Nichola L Davies, Camila de-Almeida, Sebastien L Degorce, Myriam Didelot,[...]. J Med Chem 2018
32
100


ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.
Andrew N Blackford, Stephen P Jackson. Mol Cell 2017
575
100

DNA damage response (DDR) via NKX3.1 expression in prostate cells.
Burcu Erbaykent-Tepedelen, Selda Karamil, Ceren Gonen-Korkmaz, Kemal S Korkmaz. J Steroid Biochem Mol Biol 2014
15
100

Heterogeneity of genomic profile in patients with HER2-positive breast cancer.
Bo Chen, Guochun Zhang, Guangnan Wei, Yulei Wang, Liping Guo, Jiali Lin, Kai Li, Hsiaopei Mok, Li Cao, Chongyang Ren,[...]. Endocr Relat Cancer 2020
8
100

Super-enhancers in transcriptional regulation and genome organization.
Xi Wang, Murray J Cairns, Jian Yan. Nucleic Acids Res 2019
27
100

Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
Siqing Fu, Yudong Wang, Khandan Keyomarsi, Funda Meric-Bernstam, Funda Meric-Bernstein. Expert Opin Investig Drugs 2018
18
100

Clustered DNA Double-Strand Breaks: Biological Effects and Relevance to Cancer Radiotherapy.
Jac A Nickoloff, Neelam Sharma, Lynn Taylor. Genes (Basel) 2020
34
100

BRCA2 and Other DDR Genes in Prostate Cancer.
Paz Nombela, Rebeca Lozano, Alvaro Aytes, Joaquin Mateo, David Olmos, Elena Castro. Cancers (Basel) 2019
33
100

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
Ulrich Lücking, Lars Wortmann, Antje M Wengner, Julien Lefranc, Philip Lienau, Hans Briem, Gerhard Siemeister, Ulf Bömer, Karsten Denner, Martina Schäfer,[...]. J Med Chem 2020
2
100

The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
Yue Zhao, Liu-Xia Zhang, Ting Jiang, Jing Long, Zhong-Ye Ma, Ai-Ping Lu, Yan Cheng, Dong-Sheng Cao. Eur J Med Chem 2020
11
100

Genomic characterization of metastatic breast cancers.
François Bertucci, Charlotte K Y Ng, Anne Patsouris, Nathalie Droin, Salvatore Piscuoglio, Nadine Carbuccia, Jean Charles Soria, Alicia Tran Dien, Yahia Adnani, Maud Kamal,[...]. Nature 2019
170
100

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy.
Elisabeth A Messner, Thomas M Steele, Maria Malvina Tsamouri, Nazila Hejazi, Allen C Gao, Maria Mudryj, Paramita M Ghosh. Biomedicines 2020
10
100


DNA repair: Damage alert.
Jiri Bartek, Jiri Lukas. Nature 2003
45
100

Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Lin Mei, Junran Zhang, Kai He, Jingsong Zhang. J Hematol Oncol 2019
41
100

DNA double-strand break repair pathway choice - from basic biology to clinical exploitation.
Ron D Jachimowicz, Jonas Goergens, H Christian Reinhardt. Cell Cycle 2019
13
100

Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target.
Mu Yao, Linda Rogers, Natalka Suchowerska, Daniel Choe, Mahmoud A Al-Dabbas, Ramit S Narula, J Guy Lyons, Paul Sved, Zhong Li, Qihan Dong. Radiother Oncol 2018
8
100

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.
Sehhoon Park, Joonho Shim, Peter G S Mortimer, Simon A Smith, Robert E Godin, Simon J Hollingsworth, Hee-Jung Kim, Hyun Ae Jung, Jong-Mu Sun, Woong-Yang Park,[...]. Cancer 2020
4
100


First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Timothy A Yap, David S P Tan, Angelika Terbuch, Reece Caldwell, Christina Guo, Boon Cher Goh, Valerie Heong, Noor R Md Haris, Saira Bashir, Yvette Drew,[...]. Cancer Discov 2021
15
100

111In- and 225Ac-Labeled Cixutumumab for Imaging and α-Particle Radiotherapy of IGF-1R Positive Triple-Negative Breast Cancer.
Viswas Raja Solomon, Elahe Alizadeh, Wendy Bernhard, Siddesh V Hartimath, Wayne Hill, Rufael Chekol, Kris M Barreto, Clarence Ronald Geyer, Humphrey Fonge. Mol Pharm 2019
10
100

ATM in DNA repair in cancer.
Mei Hua Jin, Do-Youn Oh. Pharmacol Ther 2019
47
100

Mechanistic insights into transcription coupled DNA repair.
Bibhusita Pani, Evgeny Nudler. DNA Repair (Amst) 2017
26
100

Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Kalnisha Naidoo, Patty T Wai, Sarah L Maguire, Frances Daley, Syed Haider, Divya Kriplani, James Campbell, Hasan Mirza, Anita Grigoriadis, Andrew Tutt,[...]. Mol Cancer Ther 2018
25
100

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Noel Clarke, Pawel Wiechno, Boris Alekseev, Nuria Sala, Robert Jones, Ivo Kocak, Vincenzo Emanuele Chiuri, Jacek Jassem, Aude Fléchon, Charles Redfern,[...]. Lancet Oncol 2018
128
100

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Nadine Tung, Nancy U Lin, John Kidd, Brian A Allen, Nanda Singh, Richard J Wenstrup, Anne-Renee Hartman, Eric P Winer, Judy E Garber. J Clin Oncol 2016
240
100


When the guardian becomes the enemy: Targeting ATM in PTEN-deficient cancers.
Nuala McCabe, Steven M Walker, Richard D Kennedy. Mol Cell Oncol 2015
5
100

PARP inhibitor resistance: the underlying mechanisms and clinical implications.
He Li, Zhao-Yi Liu, Nayiyuan Wu, Yong-Chang Chen, Quan Cheng, Jing Wang. Mol Cancer 2020
21
100

Regulation of DNA repair throughout the cell cycle.
Dana Branzei, Marco Foiani. Nat Rev Mol Cell Biol 2008
771
100

Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer.
Jiri Bartek, Martin Mistrik, Jirina Bartkova. Cancer Discov 2013
25
100

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
100

Activation of Oncogenic Super-Enhancers Is Coupled with DNA Repair by RAD51.
Idit Hazan, Jonathan Monin, Britta A M Bouwman, Nicola Crosetto, Rami I Aqeilan. Cell Rep 2019
12
100



Transcriptional activation of DNA-dependent protein kinase catalytic subunit gene expression by oestrogen receptor-alpha.
Senad Medunjanin, Sönke Weinert, David Poitz, Alexander Schmeisser, Ruth H Strasser, Ruediger C Braun-Dullaeus. EMBO Rep 2010
15
100

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.
Emanuela Dylgjeri, Christopher McNair, Jonathan F Goodwin, Heather K Raymon, Peter A McCue, Ayesha A Shafi, Benjamin E Leiby, Renée de Leeuw, Vishal Kothari, Jennifer J McCann,[...]. Clin Cancer Res 2019
12
100

CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes.
Anil Paul Chirackal Manavalan, Kveta Pilarova, Michael Kluge, Koen Bartholomeeusen, Michal Rajecky, Jan Oppelt, Prashant Khirsariya, Kamil Paruch, Lumir Krejci, Caroline C Friedel,[...]. EMBO Rep 2019
23
100

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Chinnadurai Mani, Shirisha Jonnalagadda, Jojireddy Lingareddy, Sanjay Awasthi, William H Gmeiner, Komaraiah Palle. Breast Cancer Res 2019
16
100

Structural basis of homologous recombination.
Yueru Sun, Thomas J McCorvie, Luke A Yates, Xiaodong Zhang. Cell Mol Life Sci 2020
24
100

Drugging the Cancers Addicted to DNA Repair.
Jac A Nickoloff, Dennie Jones, Suk-Hee Lee, Elizabeth A Williamson, Robert Hromas. J Natl Cancer Inst 2017
75
100

PARP Inhibitors in Prostate and Urothelial Cancers.
Rohan Garje, Raju Kumar Vaddepally, Yousef Zakharia. Front Oncol 2020
9
100

Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours.
George A R Wiggins, Logan C Walker, John F Pearson. Cancers (Basel) 2020
2
100



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.